FK866 (APO866): Non-Competitive NAMPT Inhibitor for Cancer Metabolism Research

Executive Summary: FK866 (APO866) is a highly specific, non-competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with a Ki of 0.4 nM, selectively blocking NAD biosynthesis in cancer cells while sparing normal hematopoietic progenitors [APExBIO]. This results in rapid depletion of intracellular NAD and ATP, triggering caspase-independent cell death and autophagy in acute myeloid leukemia (AML) models (Ji et al., 2025). FK866 demonstrates robust in vivo antitumor efficacy, improving survival and preventing tumor growth in xenograft models. It is widely used in research on cancer metabolism targeting and is available from APExBIO as SKU A4381. The compound requires careful handling and storage due to its solubility and stability profile.

Biological Rationale

Nicotinamide phosphoribosyltransferase (NAMPT) is a rate-limiting enzyme in the salvage pathway of NAD biosynthesis. NAD is essential for cellular metabolism, DNA repair, and survival. Cancer cells exhibit elevated NAD turnover, making them especially dependent on NAMPT activity (Ji et al., 2025). Inhibition of NAMPT disrupts NAD homeostasis and can selectively target cancer cell viability, particularly in hematologic malignancies such as AML. Targeting cancer metabolism via NAD biosynthesis inhibition is an emerging therapeutic strategy [Related: Mechanistic Underpinnings of NAMPT Inhibition]. This article extends previous coverage by detailing FK866-specific parameters and evidence benchmarks.

Mechanism of Action of FK866 (APO866)

FK866 (APO866) is a non-competitive inhibitor of NAMPT, binding outside the active site and irreversibly blocking enzyme function. The compound exhibits a Ki of 0.4 nM and reported IC50 values in cellular assays ranging from 0.09 nM to 27.2 nM, depending on cell type and assay buffer conditions [APExBIO Product Page]. Inhibition of NAMPT blocks the conversion of nicotinamide to nicotinamide mononucleotide (NMN), halting NAD synthesis. Rapid depletion of NAD leads to reduced ATP generation, mitochondrial membrane depolarization, and caspase-independent cell death. FK866 also induces autophagy dependent on new protein synthesis. Notably, these effects are more pronounced in AML cells than in normal hematopoietic progenitors, suggesting a therapeutic window [see: Precision Targeting in AML Research]. This article clarifies FK866’s unique selectivity profile and underlying mechanism.

Evidence & Benchmarks

• FK866 inhibits recombinant NAMPT with a Ki of 0.4 nM at 25°C in Tris-HCl buffer, pH 7.4 (APExBIO Product Data, product page).
• In cellular assays, FK866 displays IC50 values ranging from 0.09 nM (AML cell line OCI-AML3) to 27.2 nM (various solid tumor lines) under normoxic conditions (APExBIO, product page).
• FK866 treatment results in >90% reduction of intracellular NAD and ATP within 24 hours in AML cells, with minimal effect on normal human hematopoietic progenitors (Ji et al., 2025, DOI).
• Cell death induced by FK866 is caspase-independent and involves mitochondrial membrane depolarization, as shown in AML xenograft models (Ji et al., 2025, DOI).
• FK866 demonstrated significant antitumor efficacy in vivo, preventing tumor establishment and improving survival in mouse AML and lymphoblastic lymphoma xenografts (Ji et al., 2025, DOI).
• FK866 is insoluble in water but soluble in DMSO (≥19.6 mg/mL) and ethanol (≥49.6 mg/mL); stable for several months at -20°C (APExBIO, product page).

Applications, Limits & Misconceptions

FK866 (APO866) is used extensively in preclinical research to dissect cancer metabolism and test the therapeutic potential of NAD biosynthesis inhibitors. Key applications include:

• Selective targeting of AML and other hematologic cancer cells with high NAD turnover.
• Modeling metabolic vulnerabilities and cell death pathways in cancer.
• Evaluating caspase-independent apoptosis and mitochondrial dynamics.
• Testing combination strategies with DNA-damaging agents and PARP inhibitors.

For further practical protocols, see 'NAMPT Inhibitor Workflows for AML Research'. This article updates those workflows with new storage and dosing stability insights.

Common Pitfalls or Misconceptions

• FK866 is not effective in cells with alternative NAD biosynthesis routes (e.g., via nicotinic acid phosphoribosyltransferase).
• FK866 does not induce classic caspase-dependent apoptosis; cell death is mainly caspase-independent.
• Solubility is limited in aqueous buffers; improper dissolution can lead to precipitation and reduced efficacy.
• FK866's selectivity window is narrow; high concentrations may affect non-malignant cells in some primary cultures.
• Long-term storage above -20°C or repeated freeze-thaw cycles reduce compound potency.

Workflow Integration & Parameters

FK866 (APO866), available from APExBIO (A4381), should be prepared as a stock solution in DMSO or ethanol. For in vitro studies, dilute stock to final working concentrations (0.1–50 nM) in culture medium immediately before use. Store stock solutions at -20°C and avoid repeated freeze-thaw cycles. For in vivo work, FK866 is typically administered at 2–10 mg/kg/day in mouse models, with dosing regimens tailored to tumor burden and model sensitivity (Ji et al., 2025). Always confirm solubility and stability prior to use.

For broader context on translational design and future directions, see 'NAMPT Inhibition and the Future of Cancer Metabolism'. This article provides updated evidence and practical handling guidance for FK866 users.

Conclusion & Outlook

FK866 (APO866) is a validated, non-competitive NAMPT inhibitor with robust selectivity for cancer cells reliant on NAD biosynthesis. Its unique mechanism—depleting NAD/ATP and inducing caspase-independent death—makes it a critical tool for studying cancer metabolism and developing targeted therapies. With well-characterized storage and workflow parameters, FK866 continues to support rigorous, reproducible research in hematologic oncology and beyond. For ordering and datasheets, visit the APExBIO product page.